MaxCyte, Inc. is a Rockville, Maryland-based cell-engineering company that provides enabling platform technologies for the discovery, development, and commercialization of next-generation cell therapies. Its core offering is the proprietary Flow Electroporation technology and the ExPERT platform, which allow biopharmaceutical and biotechnology customers to engineer a wide range of cell types and payloads. The company also offers gene-editing risk assessment services through its SeQure portfolio, including ONE-seq and GUIDE-seq, as well as newly launched CHANGE-seq-BE and ONE-seq-BE tools for evaluating off-target editing.
MaxCyte generates revenue through instrument sales and single-use processing assemblies, and increasingly through Strategic Platform License agreements under which partners pay annual fees, milestones, and royalties as programs advance toward and through commercialization. Because its platform supports many cell and gene therapy developers, investors follow MXCT as a broad, pick-and-shovel exposure to the cell therapy sector. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Over the last 30 days, MXCT has risen from about $1.18 to approximately $1.69, a gain of roughly 43%. The advance was not linear: shares drifted lower through early October, reaching near $0.96 on October 13, before staging a decisive rally on October 14 that lifted the stock above $1.25 in a single session on sharply elevated volume.
The trailing quarter tells a similar but more pronounced story. From roughly $1.00 in late July, the stock has gained more than 60% to current levels. The broader trend reflects improving operating momentum rather than a single isolated event, though short-term moves have remained volatile given the company's relatively small float and lower trading liquidity.
The primary catalyst was the October 14 announcement of preliminary third-quarter 2026 results and raised guidance. MaxCyte reported core business revenue of approximately $8.1 million, up 26% from the prior-year period, and SPL Program-related revenue of more than $1.0 million, including a $1.0 million milestone. The company raised its full-year 2026 revenue outlook to approximately $34 million, up from a prior range of $30 million to $32 million, with core business revenue expected near $28 million and SPL-related revenue near $6 million.
Investors responded by sending the stock up about 25% in a single session, with volume surging to more than 7.6 million shares versus a typical daily average well under one million. Management noted that the outperformance was driven in part by accelerated instrument purchasing from a large customer originally expected in the fourth quarter, along with a milestone from an SPL partner. Analysts have cautioned that a portion of the beat reflects the timing of a pulled-forward sale and that a share of the raised guidance includes one-time milestone revenue, making the durability of the growth a key focus. From what I see, this timing element deserves close attention in the coming quarters.
The quarterly advance reflects a broader narrative of a return to growth. After a challenging 2025, management entered 2026 targeting a second-half inflection, and the third-quarter update delivered evidence of double-digit revenue growth. Supporting sentiment, MaxCyte announced in July 2026 a multi-platform technology license agreement with Genentech to advance cell therapy development, expanding an enterprise partnership model that underscores the value of its SPL strategy.
Additional developments reinforced the theme, including the August 2026 launch of CHANGE-seq-BE and ONE-seq-BE for off-target assessment and the September appointment of a Chief Corporate Development Officer. Management has also emphasized that the company supports more late-stage clinical programs under its SPL partnerships than ever before, including two pivotal trials with potential for regulatory approval as early as next year. I’m watching this closely as the pipeline depth could provide further support.
Investors should monitor MaxCyte's third-quarter 2026 earnings call, scheduled for November 10, when full financial results including royalty revenue will be reported. Key areas of focus include the quality and sustainability of core revenue growth, whether the pulled-forward instrument purchases lead to a lighter fourth quarter, and any updates on SPL milestone and royalty activity. Progress on partner clinical programs—particularly the two pivotal trials management has highlighted—and any new Strategic Platform License agreements will be important demand signals. Macroeconomic conditions affecting biotech funding and sentiment toward the broader cell and gene therapy sector could also influence trading, especially given MXCT's comparatively small market capitalization and above-average volatility. One thing that stands out is how these factors could shape near-term volatility.
In my view, reviewing data-driven strategies can complement fundamental analysis for stocks like MXCT. Tickeron’s Trending AI Robots page offers a curated look at top-performing automated trading strategies. These bots cover different timeframes and risk profiles, providing a practical way to evaluate systematic ideas that align with individual objectives without replacing manual research.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The 10-day RSI Indicator for MXCT moved out of overbought territory on October 30, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 instances where the indicator moved out of the overbought zone. In 23 of the 25 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for MXCT turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 40 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.
The 10-day moving average for MXCT crossed bearishly below the 50-day moving average on November 17, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MXCT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
MXCT broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 55 of 65 cases where MXCT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Momentum Indicator moved above the 0 level on November 20, 2026. You may want to consider a long position or call options on MXCT as a result. In 72 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
MXCT moved above its 50-day moving average on November 18, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +9.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where MXCT advanced for three days, in 199 of 251 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
The Tickeron Valuation Rating of 27 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.819) is normal, around the industry mean (4.142). P/E Ratio (-3.706) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (4.092) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. MXCT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 59 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MXCT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry MedicalNursingServices